Third Harmonic Bio Inc. (THRD): Price and Financial Metrics
GET POWR RATINGS... FREE!
THRD Stock Price Chart Interactive Chart >
THRD Price/Volume Stats
| Current price | $4.04 | 52-week high | $24.59 |
| Prev. close | $4.07 | 52-week low | $3.75 |
| Day low | $3.97 | Volume | 98,400 |
| Day high | $4.15 | Avg. volume | 147,234 |
| 50-day MA | $4.25 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 163.80M |
Latest THRD News From Around the Web
Below are the latest news stories about THIRD HARMONIC BIO INC that investors may wish to consider to help them evaluate THRD as an investment opportunity.
The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drugGene therapy firm bluebird bio can move forward with a study designed to test the drug lovo-cel in pediatric patients with sickle-cell disease |
Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?THRD stock investors are clearly disappointed after Third Harmonic Bio discontinued its clinical study over safety concerns. |
Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety ConcernsThird Harmonic Bio Inc (NASDAQ: THRD) will discontinue the ongoing Phase 1b study of THB001 in chronic inducible urticaria, after observing asymptomatic liver transaminitis in two subjects enrolled in the first dose cohort of 200mg BID. Chronic inducible urticaria is a common inflammatory skin condition characterized by the recurrence of itchy wheals and/or angioedema. The company is initiating nonclinical studies to elucidate the mechanism for the observed transaminitis, which was not predicted |
We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be presented at upcoming scientific conference -- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharm |
THRD Price Returns
| 1-mo | -6.26% |
| 3-mo | -2.18% |
| 6-mo | -75.88% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -6.05% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...